Jennifer Sheng

Also affiliated with Incyte (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials”.

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004273

N/A

0.753DataRank · unranked

21 citations

Martin Reck, Paul Nghiem, Feng Yan, Gregory E. Plautz, Hye Ryun Kim +10 more